May 28 (Bloomberg) -- Achillion Pharmaceuticals Inc., the maker of experimental hepatitis C therapies, said the company’s top scientist Milind Deshpande had been chosen to succeed retiring Chief Executive Officer Michael Kishbauch.
Deshpande, also the president of research and development, will take over after a three-month transition, Achillion said today in a statement. He joined the New Haven, Connecticut-based company in 2001 and has been its top scientist since June 2007. Kishbauch, CEO since July 2004, will remain a member of the company’s board.
Achillion has three drugs in clinical testing for hepatitis C, a liver disease estimated to affect 170 million people worldwide. The company announced April 23 that one of the drugs, ACH-3102, appeared effective in five out of eight patients, reducing the amount of the liver-destroying virus in their bloodstream to undetectable levels after 12 weeks of treatment. It has started a 50-patient trial of the compound with its main hepatitis drug, sovaprevir.
“I am humbled by the board’s decision and excited for the opportunity to bring Achillion into late-stage clinical development,” Deshpande said in the statement.
To contact the reporter on this story: Alex Wayne in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com